Arrowhead Pharmaceuticals (NASDAQ:ARWR) announces positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 targeting angiopoietin like protein 3 (ANGPTL3) for treatment for mixed dyslipidemias.
The data were presented at the European Society of Cardiology (ESC) Congress 2020.
In normal volunteers, repeat doses of ARO-APOC3 resulted in reduction in APOC3.
Maximal mean fasting lipid, lipoprotein, and apolipoprotein changes of: -75% for triglycerides (TG), -25% for low-density lipoprotein cholesterol (LDL-C), -33% for apolipoprotein B (ApoB) and +75% for high-density lipoprotein cholesterol (HDL-C).
ARO-APOC3 had a favorable safety and tolerability profile.
ARO-ANG3 Presentation Details:
Dose-dependent reduction in fasting ANGPTL3;
Maximal mean reductions in fasting lipid, lipoprotein, and apolipoprotein concentrations of: -71% in TG, -50% in LDL-C, -42% in ApoB, -34% in non-HDL-C and -47% in HDL-C.
Lipid, lipoprotein, and apolipoprotein reductions sustained to week 16.
ANGPTL3 inhibition has the potential to treat mixed dyslipidemia and decrease residual risk in patients with cardiovascular disease on guideline-recommended standard of care.
See other Companies presenting at ESC 2020 Conference: MyoKardia (NASDAQ:MYOK), Johnson & Johnson (NYSE:JNJ), Amarin (NASDAQ:AMRN), LivaNova (NASDAQ:LIVN), Philips (NYSE:PHG), Innovent Biologics (OTCPK:IVBIY).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.